From Doctor to Entrepreneur Shaping the Future of Stem Cell Transplants
Executive Summary
In this episode, Joe interviews Andrea Tüttenberg, a female founder and professor at the University Clinic of Mainz. Andrea is the co-founder of Actitrex, a biotech startup focusing on immune cell therapy. She explains the journey from being a doctor and researcher to founding a company that develops treatments to minimize or avoid severe immune responses in patients undergoing stem cell transplantation and beyond. Andrea discusses the potential impact of their therapy, their need for funding, and the importance of talent acquisition. She also shares personal insights including the influence of her children and her dual roles as a doctor and entrepreneur.
Interested in Working with us?
Have a look here: https://www.passionfroot.me/startupradio
“And we found the cell population that we activated, that we made much more potent, and where we saw in preclinical models, that we can shut down these overshooting immune responses.”
— Andrea Tüttenberg
Follow Us on Social Media!
If you are listening to our content for the 2nd time please consider following us on social media.
https://linktr.ee/startupradio
I think with these activated regulatory cells, we are really able to treat patients that have those overshooting immune responses.”
— Andrea Tüttenberg
Our Sponsor Startupraven
A startup’s journey can be a tough one, but it doesn’t have to feel like you’re alone on your quest! Invest in others’ success with us by joining our community of entrepreneurs who are building amazing things every day — no matter how big or small their ideas may seem at first glance.
The best way to find investors and cooperation partners for early-stage startups. Sign up here: https://startupraven.com/
“This severe side effect, this transplant rejection, occurs in nearly every second patient after a stem cell transplantation, even though there are therapies to prevent this …”
— Andrea Tüttenberg
Questions Discussed in the Interview
- What impressed you the most about Andrea Tüttenberg’s background and journey from being a medical doctor to a biotech entrepreneur?
- How critical is Andrea’s research in the field of overshooting immune responses, and how could it potentially impact the treatment of various diseases, including leukemia and autoimmune diseases?
- What challenges and opportunities do you think Actitrex may face as they progress from clinical trials to make their treatment more widely available?
- How do you perceive the role of Andrea’s kids in influencing her decision to found a biotech startup, and what implications could this have for the company’s future success?
- What are your thoughts on the market potential and possible impact of Actitrex’s treatment, considering the number of patients who could benefit from it in Europe and beyond?
- In terms of funding and talent acquisition, what strategies should Actitrex consider to ensure sufficient support for their clinical trials and expansion of their team?
- How significant is the ultrafast manufacturing process for the activated regulatory cells, and what advantages does it offer in comparison to traditional cell therapies that take weeks to be applicable?
- Based on this episode, what are your impressions of Andrea and her approach to entrepreneurship, including her attire preferences and dedication to her patients?
- What role do you believe investors could play in the growth and success of Actitrex, and what factors might influence their decision to invest in the company?
- Considering Actitrex’s focus on safety, efficacy, and market approval, how long do you think it will take for their treatment to become more widely accessible to patients in need?
Managing Graft Versus Host Disease in Transplant Patients: “We hope that only every 5th patient will get it or, they will get it in a much more moderate. There are grades from 1 to 4, and 4 is really incredible, and one is really mild.”
— Andrea Tüttenberg
The Video Podcast is set to go live on Thursday, February 8th, 2023
The podcast is available early to the members of our YouTube channel.
The Audio Podcast is set to go live on Thursday, February 8th, 2023
You can subscribe to our podcasts here.
Spotify
https://open.spotify.com/show/3etgUOz5KWKycYHsvQv1yG?si=f0b318b620dc48f0
Apple Podcasts
https://podcasts.apple.com/us/podcast/startuprad-io-the-authority-on-german-swiss-and/id967788304
Castbox
https://castbox.fm/channel/5589808?country=de
Global Podcast Network (Formerly NY City Podcast Network)
Good Pods
The Founder
Andrea Tüttenberg (https://www.linkedin.com/in/andrea-t%C3%BCttenberg-9a1520116/) is a remarkable female founder and entrepreneur in the biotech industry. Andrea is the co-founder of ActiTrexx, a biotech startup focused on developing treatments for severe immune responses and immune-mediated diseases. With a background in medicine, Andrea has a strong foundation in clinical research and experience as a doctor, a professor at the University Clinic of Mainz, and a recipient of prestigious awards in the field of research and academia. Her journey from medical doctor to researcher and now entrepreneur is a testament to her passion for pushing the boundaries of medical science to create impactful treatments for patients in need.
Andrea’s dedication to both her professional and entrepreneurial roles is evident in her commitment to co-developing innovative therapies for patients with severe immune-related conditions, such as graft-versus-host disease and transplant rejection. Her expertise in the field of immunology and her steadfast resolve to bring potential solutions from the lab to the clinic highlight her forward-thinking approach to addressing critical medical challenges. As ActiTrexx continues its clinical trials and seeks further funding, Andrea’s leadership and vision position her as a prominent figure in the biotech industry, driving groundbreaking advancements in cutting-edge medical treatments.
The Startup
Andrea Tüttenberg is the co-founder of Actitrex (https://www.actitrexx.de/), a pioneering biotech startup focused on developing a novel cell therapy to treat severe immune responses in patients undergoing stem cell transplantation for conditions such as leukemia. Actitrex is waiting for the first patient for its clinical trials. As the company gears up for the next stage of development, Actitrex is actively seeking series B funding to support its expansion and the advancement of its groundbreaking therapy.
What sets Actitrex apart is its innovative approach to leveraging activated regulatory cells to suppress overshooting immune responses, a process that has the potential to revolutionize stem cell transplantation and address critical unmet medical needs. Actitrex’s mission to broaden access to stem cell transplantation by mitigating the risk of transplant rejection positions the company as a game-changer in the field of cell therapy. With its focus on ultrafast manufacturing and a commitment to safety and efficacy, Actitrex is at the forefront of developing a therapy that could significantly impact the lives of thousands of patients worldwide.
Venture Capital Funding
ActiTrexx is fundraising their Series B funding. You can reach out to us or Andrea via her LinkedIn Profile.
Hiring!
ActiTrexx will soon be hiring again. You can check their jobs website here: https://www.actitrexx.de/jobs.html
Tune in to our Internet Radio Station here:
Join more than 170.000 monthly listeners and stay ahead of the curve with content from more than a dozen amazing creatives for everything you need to know for Tech Entrepreneurship!
Links / Further Readings / Additional Resources
- Graft-Versus-Host Disease https://www.ncbi.nlm.nih.gov/books/NBK538235/#:~:text=Introduction,the%20tissues%20of%20the%20recipient.
- Leukemia https://en.wikipedia.org/wiki/Leukemia
- Stem cell transplantation: https://www.lls.org/treatment/types-treatment/stem-cell-transplantation
Feedback
We are always looking for ways to make the show better. Please take this opportunity and share your feedback with us! We would love to hear from YOU!!!
https://forms.gle/mLV6mVKwGwKuut8BA
The Interviewer
This interview was conducted by Jörn “Joe” Menninger, startup scout, founder, and host of Startuprad.io. Reach out to him:
Keep Up to Date
Here is our publication calendar: https://calendar.google.com/calendar/embed?src=012i27ak525qi3smgjl8v9tbio%40group.calendar.google.com&ctz=Europe%2FBerlin
Automated Transcript
Jörn “Joe” Menninger [00:00:00]:
Hello. And welcome, everybody. This is Joe from Startupradio. Io, your startup podcast and YouTube blog from Germany. Today, I would like to welcome, a female founder. Finally, I’m trying to get as many female founders as I Ken. And I do have Andrea here. Hey.
Jörn “Joe” Menninger [00:00:17]:
How you doing?
Andrea Tüttenberg [00:00:18]:
Hi. Hi, Dale. Fine. Thank you. Thank you very much for having me here today.
Jörn “Joe” Menninger [00:00:23]:
Totally my pleasure. As the people who are watching this can already see, your company is called Actitrex? Is that the right pronunciation? Yeah.
Andrea Tüttenberg [00:00:33]:
That’s
Jörn “Joe” Menninger [00:00:33]:
it. And it’s a biotech startup from the city I was born in, the city of Mainz. But we’ll soon get into that. 1st, let us talk a little bit about who you are and what you did. And for everybody Who’s out there? I might tell them you’re not only a Trea, you’re also a professor at the University Clinic of Mainz. You also have your PhD and you’ve You’ve gotten a lot of awards. Wait. I was scanning through your CV and this is just some of the highlights scholarship of the German National Academic Foundation, Dagmar Eisner Research Award University Mainz Scholarship, Keikof Rose Foundation award for outstanding qualified junior scientist, University of Mainz, 2 Oncology Award for from the Society of Dermatological Research, winner of Business Plan Competition Science For Life.
Jörn “Joe” Menninger [00:01:29]:
And And I could go on. So that that is pretty impressive. Can you tell us a little bit how you actually started out? Because my understanding is you you you studied medicine from the start. Right?
Andrea Tüttenberg [00:01:41]:
Yeah. That’s it. I’m, I’m a medical doctor by training. And, I, actually, I I didn’t want to be a researcher or a company founder in the very beginning. I just wanted to be a doctor. And, at that time, it was really, hard to to get a job. And, I applied for the job as a dermatologist, and I got, yeah, I got a place, but it was, yeah, I I had to go to the, to the lab, in parallel. So they told me, okay.
Andrea Tüttenberg [00:02:13]:
You can come, but, we want you not only to be on the ward, but also to go and do some research. And, I was not very fan of that in the very Menninger, but, when you, or when you see that, Actually, in dermatology, there are a lot of, connections between the clinic and the research. It starts To get very interesting. And this is, why Adan did in parallel to my clinical education. I did my, yeah, my my research, And then one came to the other. And, yes, now I’m here and have founded the company.
Jörn “Joe” Menninger [00:02:51]:
Okay. So the the as the doctors usually are, they speak some very strange language. Dermatology, we may tell the audience that Skin doctor mostly. Yeah. That very much simplified. And if you talk about the word, that means that is the actual part where you cheat the patients.
Andrea Tüttenberg [00:03:09]:
Yep. That’s it. Where the patients are, either the outward, outward patients that come only for a day or So so on. Or, also, the patients that are on the yeah. That lie in the bed because they got the treatment or something like that.
Jörn “Joe” Menninger [00:03:27]:
Mhmm. I’ve I’ve seen before we get into what you did as a doctor and how it got you to be a biotech entrepreneur, I’ve seen you Studied at McGill University in Canada and, in Zurich in Switzerland. I I was wondering when I was reading this, Are you into skiing?
Andrea Tüttenberg [00:03:46]:
Yes. I am. Nevertheless, my family would laugh now because, they are much better than me. But, I I really I I am into skiing, and I, I like skiing very much because it’s also a family thing at at our home. And, yeah, Canada was a great experience because this is a complete, other health system, but Montreal is a great city. And, yeah, you could do a lot of things there in addition to working in the clinics.
Jörn “Joe” Menninger [00:04:16]:
Did you fall in love with the Montreal bagels?
Andrea Tüttenberg [00:04:19]:
Yeah. I like them very much because they are really Sweeter than the normal bagels are because they are with hammy. But I also like, the poutine there, which is Fries with, sows of, meat. This is also extraordinary, but really and maple syrup. I love maple syrup since I worked in Canada.
Jörn “Joe” Menninger [00:04:43]:
I have to admit, I I’ve never gotten into poutine, but but I’m a big fan of maple syrup, so are my boys now. Yep.
Andrea Tüttenberg [00:04:51]:
Yeah. It’s real. I I put it everywhere you can put it. Joe it’s really Fantastic stuff.
Jörn “Joe” Menninger [00:04:58]:
Yes. But but I do assume you also learned a lot there in the places, different working, different language. How was it when you treated your 1st patient in Canada? To to to do it in English, Were you scared out of your mind?
Andrea Tüttenberg [00:05:15]:
No. That’s quite okay. With English, it was quite okay. I I have to admit, I choose Canada and Montreal especially because, Normally, I like much more to speak French. And I also can speak a lot better French than I can In speak English. So, I try to to have both at the same time because my parents said you only get 1 paid one Excursion, to the to to to, the foreign countries. And so, I choose Montreux because in my leisure time, I I spoke French. At The clinic has book English, and it was not that hard.
Andrea Tüttenberg [00:05:54]:
I, I don’t know why, but you read a lot of Things also in English when you’re doing your medical education. So perhaps it’s like, yeah, a little bit accustomed. But, I I, worked with kids there. And this was funny because they always said, you have to speak very slowly because she comes from the other end of the world. This was always what they did say when I started there with my English.
Jörn “Joe” Menninger [00:06:21]:
Okay. Okay. So now we know you studied abroad. You studied in Switzerland. You’ve been a skin doctor by training. Yeah. Can you tell us a little bit now how this story develops into getting, the Technology, the treatment that your company does right now and is waiting at as you said, you’re looking at the building, for your first patient to start clinical trials. Can you take us a little bit along this journey?
Andrea Tüttenberg [00:06:53]:
Yeah. Of course. First, I have to acknowledge That there is, my colleague, Hemod Joonolait, who is a little bit, the father of all this, To, he he founded with me together, and he was my mentor in the very beginning in the lab. And if you are working in the lab, you see that there are things you can bring into the clinic to the patient, and, you can bring also, things from the patient back to the To the lab. So you call it from bench to bedside because this is, yeah, yeah, this is a circle, so to say. And we did we worked with immune cells, and we tried to, induce tolerance, With, a certain, subgroup of immune cells that are cells that are located in our peripheral blood and that are naturally occurring in our peripheral blood. And, we developed those cells. We activated them, and we saw that, they are much more potent in, Yeah.
Andrea Tüttenberg [00:07:55]:
Conveying tolerance in in in, decreasing, overshooting immune responses. And an overshooting immune response is, for example, in allergy. So when you are in autoimmunity, so or in transplant rejection, Those are all diseases that go ahead with overshooting immune responses. And we found the the cell population That we activated, that we made much more potent, and where we saw in preclinical models, that we are able to shut down this overshooting immune responses. And this was the first time when we said, okay. This works really good in preclinical models. Why shouldn’t we go into the clinic and make a drug out of it? And, normally, you get funded for research With money that is enough for doing basic research, but that isn’t enough to develop a company and to found a company. And so we, applied for a grant from the Federal Ministry of, of Research and Education, because they have a program which is called GoBio and which enables you to take the steps and to have enough money to to go To to foundation of a company because you have to do regulatory stuff, which costs money.
Andrea Tüttenberg [00:09:14]:
I have to do, Yeah. A lot of things that cost more money than you get by normal grants. And this was, then the, yeah, the idea to to To try to to get, to try to develop a clinical trial and to try to found a company. And, Yeah. This was step by step. And, I think with this activated regulatory cells, we are really, able To, yeah, to treat patients that have those overshooting immune responses. And I don’t know. We will start with, something that is Called graft as a host disease, and that is, that is the severe side effect after stem cell transplantation in leukemia patients.
Andrea Tüttenberg [00:09:58]:
And those will be our 1st clinical trial helping those patients after stem cell transplantation.
Jörn “Joe” Menninger [00:10:04]:
I do have Some medical training being in EMT in the past, but I do believe for a lot of people, you could have say, blah blah, and and it would have been the same.
Andrea Tüttenberg [00:10:16]:
I tried to make it by comprehensive. What?
Jörn “Joe” Menninger [00:10:20]:
You did totally fine. Basically, let me try to dumb this down so even I would understand it.
Andrea Tüttenberg [00:10:27]:
Yeah.
Jörn “Joe” Menninger [00:10:27]:
Right now, you’re waiting for the 1st patient who has leukemia, meaning, blood cancer.
Andrea Tüttenberg [00:10:34]:
Yeah.
Jörn “Joe” Menninger [00:10:35]:
And basically, the chemotherapy erases most or all of the cells that produce blood. The patient gets a transplant. Yeah. And then there is the risk of the body rejecting it, overreacting as you said. And your treatment can, for example, help Those patients, or that is what you’re currently working on.
Andrea Tüttenberg [00:11:00]:
Yeah. Yeah. That’s completely right. So This severe side effect, this transplant rejection, this occurs in nearly every second patient after stem cell Even though there are therapies to prevent, but, they do not help in a 100%. And we try to give The patients activated cells that, dumped down the immune, the this transplant rejection. And, So they won’t get severe, inflammation at their bodies. They won’t die from this side effect, and, this is what we try to do. Yeah.
Jörn “Joe” Menninger [00:11:39]:
Do you have any idea how much better it will get from 1 in 2, maybe to 1 in 3, 1 in 5?
Andrea Tüttenberg [00:11:47]:
Yeah. We hope, we hope, that only at at the moment, every second patient will develop graft versus host disease and we, this transplant rejection. And we hope that, only every 5th, patient will get it or will or, they will get it in a much more easier no. Not easier how do you say? Moderate. Much much more moderate. You know? There are grades from 1 to 4, and 4 is really incredible, And one is really mild. And we try either to, prevent it completely or, or In in a a lot less patients or, to have a moderate form of transplant rejection. This would also be an option.
Jörn “Joe” Menninger [00:12:35]:
Mhmm. Mhmm. I see. And talking about that
Andrea Tüttenberg [00:12:39]:
point is that Yep. Sorry.
Jörn “Joe” Menninger [00:12:40]:
One
Andrea Tüttenberg [00:12:41]:
one important point. The stem cell transplantation is the only cure for leukemia patients. You have a lot of stuff, chemotherapies, and so on. But Stem cell transplantation is the only cure. And at the moment, only 10% of the patients that would need, that would need a stem cell Transplantation. Get one. And this is because of this, not only, you have to found find a compatible donor first. That’s for sure.
Andrea Tüttenberg [00:13:07]:
Mhmm. But the 2nd major hurdle or major challenge is indeed that they get this transplant rejection. And this is why only 10% worldwide, get a stem cell transplantation. So if our therapy would prevent this, this, transplant rejection, everyone who needs it would get it. And this is what we aim to.
Jörn “Joe” Menninger [00:13:29]:
How many leukemia patients are we talking every year here? Do you have
Andrea Tüttenberg [00:13:35]:
Yeah. You can see every minute worldwide someone is diagnosed with leukemia from the very little kid to the very aged person. So there are several forms that are not life threatening, but every minute, someone worldwide. Yep.
Jörn “Joe” Menninger [00:13:55]:
That makes thousands of patients.
Andrea Tüttenberg [00:13:58]:
And we have at the moment, we have about 50,000, transplants in Europe So far per year. And we could really increase this, when our therapy would would be a good one.
Jörn “Joe” Menninger [00:14:13]:
Okay. I see. So if you say right now 10% of the patients get transplant, if we have 50,000 each year, you could help somewhere additionally 300 to 500,000 somewhere in this area?
Andrea Tüttenberg [00:14:27]:
Yep. That’s it. Yeah.
Jörn “Joe” Menninger [00:14:31]:
That is quite a lot. And then we are only talking about Europe with a population of somewhere let let’s say, rule of thumb, Something like half a 1,000,000,000 people.
Andrea Tüttenberg [00:14:40]:
Yeah. But the funny thing is even, in a we are, really, per year, you have round about, Yeah. 60 to 80,000 transplantation, and, Europe is indeed, the leader in that. So we have about 40 to 45 Thousand transplantations in the US. You have about 20 to 25,000, and then comes China, and, then comes the rest of the world. So We are quite, the market is quite localized in Europe and the US, to be honest.
Jörn “Joe” Menninger [00:15:11]:
I see, nonetheless, that that’s a lot of people you could help with that. Right? Yeah.
Andrea Tüttenberg [00:15:15]:
Yeah. Fine. Definitely. And, yeah. And It is, still not only, leukemia you could treat with stem cell transplantation. I don’t know whether you heard about those HIV patients, for example. There’s 1 London patient and 1 Dusseldorf patient, so called. And they had, also stem cell transplantation, and they were cured from HIV.
Andrea Tüttenberg [00:15:37]:
And at the moment, you wouldn’t give HIV patients a stem cell transplantation because of this severe side effect. But, nonetheless, if this is done, You also have treatment options in this direction. So you can you can have, yeah, some Some or some other indications that, could be treated or prevented with this, with this treatment modality.
Jörn “Joe” Menninger [00:16:01]:
Mhmm. In my understanding is this is your, let’s say, starting point because with your approach, with the, how do you call it? Treatment of the of those cells, how what how are those cells called?
Andrea Tüttenberg [00:16:17]:
So those are regulatory cells, and they are activated. So we activate them because, Yeah. They normally, they do their job, but, when you want to make them more potent and you want to give them kind of a turbo or booster or Something like that, you can activate them. And this is a process which is also, very, very fast. So it’s an ultrafast manufacturing process. You get the cells. You isolate them, deactivate them, and you give them back. It’s within 24 hours.
Andrea Tüttenberg [00:16:44]:
Normally, cell therapies need about 3 to 6 weeks To to be applicable. But, this is not beneficial for patients who are really ill. So, the most precious thing is, time for them. And so our ultrafast approach is really, I think, beneficial for the patients.
Jörn “Joe” Menninger [00:17:07]:
I see. I see. That’s very, very interesting. I and my understanding is that is your starting point, like, leukemia, stem cell transplants, maybe HIV patients, but also like, autoimmune diseases and and much more is theoretically at least possible with this approach.
Andrea Tüttenberg [00:17:30]:
Yep. Yep. That’s it. You could compare it to every disease that is, associated with, those overshooting immune responses. So Exactly.
Jörn “Joe” Menninger [00:17:43]:
I’m a professor of medicine. What else is out there?
Andrea Tüttenberg [00:17:48]:
Yeah. For example, if, Yeah. If you name 1 disease, could be, for example, multiple sclerosis, which is also, a very, Yeah. High impact disease. You could also go with autoimmune diseases of the skin. Yeah. But I I think there are several possibilities. But I think, every everything is, in direction, overshooting immune responses.
Andrea Tüttenberg [00:18:16]:
And this is also severe allergy syndromes or something like that. But, therefore, we still have to develop or we still have to do preclinical data and Joe this is always the steps you have to do. You have to have an idea, then you have to do some basic research, then you have to do some Preclinical work, and then you have to discuss with the regulatory authorities, and then you can probably enter into a clinical trial. And, yeah.
Jörn “Joe” Menninger [00:18:41]:
Before we get into, the the the actual startup process for you, I had a question. Yes. I was wondering where we are right now in this, state because if somebody out there has leukemia, This is not an available treatment right now. As we said, you’re waiting for the very first patient here. So this is really, really very early stage.
Andrea Tüttenberg [00:19:07]:
Yeah. It’s quite, it’s at the moment, it’s it’s really a clinical trial with, some patients, to to, look for safety. And this is always the 1st step. And if we are good at safety, then we can do the next step with some more patients, a 100 or something like that, 70 to 100 patients to prove efficacy. So to show that, really, our cells do what they have to do. And And then you have to go for market approval. But this will completely right. This will take another 2 to 3 years.
Andrea Tüttenberg [00:19:40]:
And, this is, yeah, Always, remarkable that this all takes this time, but it’s like that. It’s for the safety of the patients on the other And so, it’s, yeah. It has a reason that it takes time.
Jörn “Joe” Menninger [00:19:56]:
It totally makes sense. Now that, People including me even understand what you’re doing. I when we talked before this interview, that was very very interesting because, one of the forces for you founding your startup, your biggest supporters to go to a biotech startup have actually been your kids?
Andrea Tüttenberg [00:20:20]:
Yeah. That’s, that’s it. It’s, it was really A big step. So I started as a doctor. I did a lot of research. And when this came up, that I had the Possibility to found the company with my colleague, I was really hesitating because, I like to be a doctor, I have to say, I really like my patience and my job. I’m, in the oncology dealing with skin cancers. I was I was in the oncology dealing with skin cancers.
Andrea Tüttenberg [00:20:52]:
I really was a fan of that. And my kids said, okay. But You can make, your therapy available to a lot more patients than if you stay at the ward, or in the clinics And do a little bit of basic research. And, and they told me if it doesn’t work, you even you have had Really good experience. And, you learned a lot. And, you can still do other things after that. And so it was like, they didn’t see this, as, they did they wouldn’t fear it. So, and they said, try it.
Andrea Tüttenberg [00:21:29]:
And Only if you try it, you can see what happens. And so, yes, we discuss it a lot at our dine dinner table In the evenings. And, yeah, they they said try it, and, I think, that was really good. Yeah.
Jörn “Joe” Menninger [00:21:47]:
How are you?
Andrea Tüttenberg [00:21:47]:
Account.
Jörn “Joe” Menninger [00:21:48]:
Yeah. And just to tease you here a tiny bit, How how much do you think it is earned by your kids, being, Oh, like it much more to say, oh, my mom is biotech entrepreneur than, oh, my mom is doctor. Isn’t it a little bit fancier?
Andrea Tüttenberg [00:22:09]:
Yeah. I think it depends who who whom you would ask. I think my son is in this direction. Chen, yes. And I think my daughter is more, the she she is quite neutral to that. But, I think it’s it’s still both because, yeah, As I’m doing clinical trials, I I’m still, training my medical, brain, so to say. And I have to To bring in my knowledge because I’m also responsible for the clinical trial and the building up of the clinical trials. And, so it’s, it’s quite helpful that I I’m a doctor.
Andrea Tüttenberg [00:22:44]:
But, yeah, it’s, so in the very Menninger, they were really, Proud to say. Yeah. We have now an entrepreneur in our family.
Jörn “Joe” Menninger [00:22:54]:
That is good. And the the the Joe only little downside when you founded the startup, you told me before, some of your patients has been sad, has have been very sad What when you left their treatment in order to found a company. Yeah. Don’t don’t worry. Another doctor took over. It’s just they they missed you as a person. Right?
Andrea Tüttenberg [00:23:14]:
Yeah. Yeah. Yeah. Yeah. Yeah. We we have enough, really good doctors here, and, they are also, yeah, really nice persons and people. But It’s always yeah. It’s it’s nice when when you have such good feedback from your patients, that They are glad that you found a company because they also told me that’s a good idea to go the next step, because You were a doctor.
Andrea Tüttenberg [00:23:39]:
You, did research, and now the next step is to develop medications or therapies. But they were sad, and that was nice feedback. I was happy.
Jörn “Joe” Menninger [00:23:51]:
That that is good. Out always what makes you happy. So, Usually, we start now with the next steps. I think we we have been there very much already. So you’re waiting for your 1st patient and 2 to 3 years until this treatment gets more available.
Andrea Tüttenberg [00:24:08]:
Hopefully. Yes.
Jörn “Joe” Menninger [00:24:10]:
Hopefully. Okay. So I do believe this will not be the last interview with you. I I really enjoyed that here. And And also Joe, most people will listen to this interview. We may tell the audience that you are here the classical one wearing the hoodie. And, then I said, oh, you’re really classic here. You’re wearing a hoodie as an entrepreneur, and you told me, oh, I prefer that of of a more formal clothing.
Andrea Tüttenberg [00:24:38]:
Yeah. It’s it’s like that, really. I I like my doctor coat or, wearing a hat hoodie. So it’s it’s my preference. Yeah.
Jörn “Joe” Menninger [00:24:46]:
Ah, okay. I see. For, the people out there who have heard it and who may have a few 1,000,000 to invest, Are you open to talk to investors?
Andrea Tüttenberg [00:24:56]:
Yeah. Yeah. For sure. We really need, a a series b funding, in in a few months because, We have now, when we finished our phase one clinical trial, we want to do the next step to go into the phase 2, 3, clinical trial until market approval. And, therefore, we we, we need, the next, fundraising. So we are really actually Discuss with investors. But, yeah, we are happy for anyone who who who wants to do it, who wants to do good things and to invest in our company, helping to build up this, this idea. Yeah.
Jörn “Joe” Menninger [00:25:36]:
Mhmm. Everybody who’s listening to this or watching this down here in the show notes, they will be linked either to your personal LinkedIn profile or to the company’s website. So both both should work unless you’re sick. Per personal experience. Yeah. We’ve we’ve we’ve both been going through the, the the the flu time
Andrea Tüttenberg [00:25:57]:
here Yeah. Yeah.
Jörn “Joe” Menninger [00:25:58]:
In Germany. Are you also looking for talent, meaning people to hire?
Andrea Tüttenberg [00:26:05]:
Yeah. Actually, yes. Because, at the moment, we we have Few people who, do the manufacturing on the one hand and research on the other hand, I think, in the next fundraising or in the next round, we will have to to enlargen our team, as well as the manufacturing, side, but also at the researcher’s Right. Because, we are as I told, we are developing, a new product pipeline, and we always need people, that help us, to do so. Mhmm.
Jörn “Joe” Menninger [00:26:42]:
And for everybody who’s now interested, again, go down here in the show notes. There will be a link to your company website and your career website. Yeah. Andrea, it has been very much a pleasure talking to you.
Andrea Tüttenberg [00:26:54]:
Thank you
Jörn “Joe” Menninger [00:26:55]:
very much. Of luck, for First, the, clinic you tried. Secondly, the fundraising. And thirdly, all of your patients.
Andrea Tüttenberg [00:27:03]:
Thank you very much. Was a pleasure for me.
Jörn “Joe” Menninger [00:27:06]:
Totally my pleasure. Have a good day and let us know when you’re seriously funding Yeah. Roles in For sure. Thank you very much.
Andrea Tüttenberg [00:27:12]:
Ciao. Thanks for having me. Ciao.
Jörn “Joe” Menninger [00:27:14]:
Have a good day. Bye bye.
